Medtronic is picking up steam with recent product launches, and its balance sheet is a fortress. Read more about MDT stock ...

Medtronic has reported new clinical data from the study of its Evolut transcatheter aortic valve replacement (TAVR) system, which is anticipated to offer fresh insights for global implanters ...

Medtronic plc’s MDT strength in the Cardiovascular business is poised to drive growth in the upcoming quarters. The company’s ...

Risk for bleeding events is significantly affected by DOAC score in patients with atrial fibrillation who have received TAVR.

The year saw much-anticipated data on the value of early TAVI vs surveillance, plus two new tricuspid device approvals.

Analyst Barclays analyst initiates Positive coverage on Anteris Technologies, forecasting a 4%-5% U.S. TAVR market share for DurAVR by 2030.

MEDTRONIC (U.S.) Medtronic is a global leader ... designed for transcatheter aortic valve replacement (TAVR) with features that ensure superior sealing and durability for patients with severe ...